ES2130219T3 - Moleculas para una administracion por iontoforesis. - Google Patents

Moleculas para una administracion por iontoforesis.

Info

Publication number
ES2130219T3
ES2130219T3 ES93300166T ES93300166T ES2130219T3 ES 2130219 T3 ES2130219 T3 ES 2130219T3 ES 93300166 T ES93300166 T ES 93300166T ES 93300166 T ES93300166 T ES 93300166T ES 2130219 T3 ES2130219 T3 ES 2130219T3
Authority
ES
Spain
Prior art keywords
less
approximately
groups
amino acids
iontophoresis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93300166T
Other languages
English (en)
Inventor
Burton H Sage
Randal A Hoke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25239567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2130219(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co
Application granted granted Critical
Publication of ES2130219T3 publication Critical patent/ES2130219T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)

Abstract

LA INVENCION PRESENTA PEPTIDOS Y PROTEINAS PARA UN SUMINISTRO IONTOFORETICO. DE MANERA ESPECIFICA SE PRESENTAN LOS METODOS PARA EL SUMINISTRO IONTOFORETICO DE GRUPOS DE AMINOACIDOS QUE CONSISTEN EN LA MODIFICACION DE DICHOS GRUPOS DE AMINOACIDOS EN UN PUNTO ISOELECTRICO MENOR DE 4,0 APROXIMADAMENTE O MAYOR DE 7,3 APROXIMADAMENTE CON UNA CARGA ELECTROSTATICA DE MAS O MENOS 1 Y UNIDADES CON GRUPOS DE AMINOACIDOS CON PUNTOS ISOELECTRICOS MENORES DE 4,0 APROXIMADAMENTE O MAYORES DE 7,3 APROXIMADAMENTE CON UNA CARGA ELECTROSTATICA DE MAS O MENOS 1.
ES93300166T 1992-01-22 1993-01-12 Moleculas para una administracion por iontoforesis. Expired - Lifetime ES2130219T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82373092A 1992-01-22 1992-01-22

Publications (1)

Publication Number Publication Date
ES2130219T3 true ES2130219T3 (es) 1999-07-01

Family

ID=25239567

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93300166T Expired - Lifetime ES2130219T3 (es) 1992-01-22 1993-01-12 Moleculas para una administracion por iontoforesis.

Country Status (7)

Country Link
US (1) US5494679A (es)
EP (1) EP0552878B2 (es)
JP (1) JP2506543B2 (es)
AU (1) AU665046B2 (es)
CA (1) CA2087087C (es)
DE (1) DE69323913T2 (es)
ES (1) ES2130219T3 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
GB9312351D0 (en) * 1993-06-16 1993-07-28 Ici Plc Thermal transfer printing dyesheet
US5843015A (en) * 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
WO1995028145A1 (en) * 1994-04-18 1995-10-26 The Procter & Gamble Company Iontophoretic delivery of bisphosphonates to the alveolar bone
US5747453A (en) 1995-06-06 1998-05-05 Alza Corporation Method for increasing the electrotransport flux of polypeptides
IT1285405B1 (it) * 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5676648A (en) 1996-05-08 1997-10-14 The Aps Organization, Llp Iontophoretic drug delivery apparatus and method for use
US6385487B1 (en) 1996-05-08 2002-05-07 Biophoretic Therapeutic Systems, Llc Methods for electrokinetic delivery of medicaments
US6333189B1 (en) 1996-06-06 2001-12-25 Alza Corporation Method of making an electrotransport device
AU3404197A (en) * 1996-06-19 1998-01-07 Becton Dickinson & Company Iontophoretic delivery of cell adhesion inhibitors
HUP0003349A3 (en) 1997-05-14 2001-12-28 Aventis Pharmaceuticals Inc Co Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
EP0898962A1 (en) * 1997-08-28 1999-03-03 Becton, Dickinson and Company Transdermal patches and methods for inactivating skin proteases
WO1999018797A1 (en) 1997-10-09 1999-04-22 Emory University Method and devices for transdermal delivery of lithium
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
USRE37796E1 (en) 1997-12-16 2002-07-23 Biophoretic Therapeutic Systems, Llc Methods for iontophoretic delivery of antiviral agents
US6148231A (en) * 1998-09-15 2000-11-14 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes and method
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6792306B2 (en) * 2000-03-10 2004-09-14 Biophoretic Therapeutic Systems, Llc Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
US7127285B2 (en) * 1999-03-12 2006-10-24 Transport Pharmaceuticals Inc. Systems and methods for electrokinetic delivery of a substance
CH696701A5 (de) * 2001-12-18 2007-10-15 Hoffmann La Roche Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen.
EP2119469B1 (en) * 2007-02-06 2014-05-14 Hisamitsu Pharmaceutical Co., Inc. Microneedle device for diagnosis of allergy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5314072B2 (es) * 1973-09-29 1978-05-15
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4585652A (en) * 1984-11-19 1986-04-29 Regents Of The University Of Minnesota Electrochemical controlled release drug delivery system
US5250022A (en) * 1990-09-25 1993-10-05 Rutgers, The State University Of New Jersey Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
JPS63102768A (ja) * 1986-10-20 1988-05-07 山之内製薬株式会社 イオントフオレ−シス用の新規プラスタ−構造体
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
AU609769B2 (en) * 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US4965343A (en) * 1988-01-28 1990-10-23 Hoffmann-La Roche Inc. Method of peptide synthesis
GB8806893D0 (en) * 1988-03-23 1988-04-27 Unilever Plc Cosmetic composition
EP0429842B1 (en) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
IT1244030B (it) * 1989-12-21 1994-06-28 Elan Corp Plc Dispostitivo in due parti per la somministrazione controllata di un ingrediente
JPH04224770A (ja) * 1990-12-26 1992-08-14 Teijin Ltd イオントフォレーシス用装置
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5203768A (en) * 1991-07-24 1993-04-20 Alza Corporation Transdermal delivery device

Also Published As

Publication number Publication date
US5494679A (en) 1996-02-27
JP2506543B2 (ja) 1996-06-12
DE69323913T2 (de) 1999-10-14
CA2087087A1 (en) 1993-07-23
AU665046B2 (en) 1995-12-14
EP0552878A2 (en) 1993-07-28
EP0552878B2 (en) 2002-11-20
CA2087087C (en) 2000-07-18
DE69323913D1 (de) 1999-04-22
JPH05345727A (ja) 1993-12-27
EP0552878A3 (en) 1993-08-25
AU3190593A (en) 1993-07-29
EP0552878B1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
ES2130219T3 (es) Moleculas para una administracion por iontoforesis.
ES2031806T3 (es) Factor de permeabilidad vascular humano.
FI931915A7 (fi) Ionihoidon lääkkeen antoelektrodi ja menetelmä sen hydroimiseksi
ES2127831T3 (es) Unidades de expresion multicistronicas y su aplicacion.
NO306342B1 (no) Syntetiske eksitatoriske aminosyrer, farmasöytisk formulering inneholdende slike aminosyrer samt mellomprodukt
DK1019073T3 (da) Apoliprotein A-I agonister og deres anvendelse til at behandle dyslipidæmiske lidelser
DE69900746D1 (de) Gesteuerte verabreichung von peptiden oder proteinen
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
ATE288719T1 (de) Kontrollierte abgabe von pharmazeutika in der vorderen augenkammer
ATE246103T1 (de) Bodenstromversorgung fur ein elektrisches fahrzeug mit erdverbindungsvorrichtung
ATE402957T1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ES2093122T3 (es) Activacion mejorada de proteinas recombinantes.
SE8803847A0 (sv) Neuromodulerande peptid
DE69021375D1 (de) Elektrisch leitfähiger klebstoff.
SE9403526D0 (sv) New Peptides
DE69836582D1 (de) Kurze peptide die die aktivität serine/threonine kinasen modulieren
ES2125873T3 (es) Plasmido hibrido para el antigeno con 38 kda de m. tuberculosis, e. coli como hospedante, el antigeno con 38 kda y una proteina con aproximadamente 33kda.
FR2768341B1 (fr) Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
IT1244496B (it) Impiego terapeutico dei peptidi della somatostatina.
BR9202374A (pt) Composicao implantavel para a administracao parenteral de uma quantidade essencialmente uniforme e continua de uma proteina,um peptideo ou polipeptideo biologicamente ativos,processo de elevar e manter elevados niveis no sangue de uma proteina,peptideo ou polipeptideo biologicamente ativos e processo para a preparacao da composicao implantavel
FI960887A7 (fi) Antimigreenilääkkeen iontoforeettinen kuljetus
DE68906066D1 (de) Peptid und dessen salze und antiallergische peptidmittel, welche diese peptide enthalten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552878

Country of ref document: ES